Preview of Teladoc’s (TDOC) Q2 Earnings: Key Points to Watch

Teladoc Health, a digital medical services platform listed on the NYSE under the symbol TDOC, is set to announce its second-quarter earnings after the market closes this Tuesday. In the previous quarter, Teladoc surpassed revenue projections by 1.7%, generating $629.4 million in revenue, marking a 2.6% decline from the previous year. The company experienced a slower period, with its EBITDA guidance for the full year falling significantly short of analysts’ expectations. Both the current and upcoming quarter’s EBITDA guidance also missed analyst estimates by a wide margin. Teladoc reported a user base of 102.5 million, reflecting an 11.7% increase from the previous year. Investors are prompted to assess whether Teladoc is a promising investment leading up to the earnings announcement.

For the upcoming quarter, analysts forecast a 3.1% year-on-year decrease in Teladoc’s revenue to $622.6 million, presenting a further slowdown from the 1.5% decline reported in the same quarter a year ago. The company is expected to post an adjusted loss of -$0.31 per share. The majority of analysts tracking Teladoc have reaffirmed their predictions in the past month, indicating a stable outlook for the company ahead of the earnings release. Over the past two years, Teladoc has fallen short of Wall Street’s revenue forecasts on five occasions. A glimpse into the results of Teladoc’s counterparts in the consumer internet sector who have already unveiled their Q2 outcomes might offer insights into Teladoc’s performance. For instance, Alphabet delivered a 13.8% revenue growth year-on-year, surpassing analysts’ projections by 2.6%, while Coursera reported a 9.8% revenue surge, exceeding estimates by 3.7%. Following their earnings announcements, Alphabet’s stock price remained steady, while Coursera’s stock soared by 36.2%.

Positive market sentiment has been observed among investors in the consumer internet segment, with average share prices climbing by 5.1% in the past month. In contrast, Teladoc’s stock has dipped by 5.9% during the same period, and analysts’ average price target for Teladoc stands at $9.16, compared to its current share price of $8.20. Amid StockStory’s recognition of the potential for thematic investing across various growth sectors such as technology and beverages, a lesser-known lucrative growth stock capitalizing on the emergence of artificial intelligence (AI) has been identified and is accessible through a provided link.

Teladoc Health’s impending earnings report has generated anticipation among investors and analysts alike, with projections hinting at a possible trend continuation for the business. As the earnings release approaches, stakeholders will be closely monitoring Teladoc’s performance and market response to the disclosed financial figures.